Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Evoq Technologies LLC Announces Launch of First Smartphone-Based Product for Retinal Health Testing

Evoq Technologies is excited to announce the FDA registration of the first in its family of products based on its proprietary smartphone-based biosensor technology. Dubbed the “SmartERG” Platform, it’s built to test the eye’s retinal health in unique ways.

PREDICTIONS-SERIES-2022About the science: By flashing a controlled light at the eye, we can evoke an electrical-physiological response from the retina that can tell us a lot about its health. When visual responses are delayed or reduced, they are often signatures of disease that lead to vision loss or blindness. That’s why our tag line is “Seeing Change in a Flash”. With the ability to collect and analyze data on a smartphone, under guidance of your healthcare provider, we are putting answers about retinal health in everyone’s hands.

Recommended AI News: 2022 TRENDS: The Year of Consumers Seeking a Brighter and More Balanced Future

Born from decades of experience of specialty engineering and research focused on ophthalmology, our first smartphone product is the Biophotometer for dark adaptation impairment testing as a Class I medical device. In 2022, Evoq will conduct clinical evaluations of its ophthalmic biosensor and specialty stimulators for submission as class II medical devices with the FDA.

Related Posts
1 of 40,347

Recommended AI News: Cybersixgill Expands Executive Team To Support Company’s Rapid Growth

Daniel Lindgren, President of Evoq Technologies, says, “Our SmartERG™ Platform will offer a revolutionary delivery method for ophthalmic patient care; with the force multipliers of simple connection of patient to provider, cloud-based analytical services, and a perfect fit for artificial intelligence. We are paving the way for cost-effective screening for retinal disease, such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, and Glaucoma effectively using the same standard-of-care as equivalent legacy diagnostic devices, but at fraction of the cost, delivered worldwide.”

Mr. Lindgren noted that Evoq Technologies is actively working with interested parties on how this technology can positively impact patient care delivery in the clinic, at the bedside, and at home. Evoq Technologies is seeking licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders who want to “Evoq a Revolution.”

Recommended AI News: Essence Report Helps Brands Unlock Potential of Social Commerce

Comments are closed.